CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 511 enrolled
Drug / intervention
Audit and Feedback +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04603560
NCT04603560N/ACompleted

Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension

Brigham and Women's Hospital·interventional·Posted Oct 27, 2020·Updated Aug 21, 2024

In Brief

A clinical study evaluating Audit and Feedback and Pharmacist E-Detailing for Hypertension. Completed, enrolled 511 participants across 1 site.

Detailed Summary

This is a three-arm pragmatic randomized controlled trial to test two interventions targeting clinical inertia in hypertension compared to control, followed by predictive modeling to identify factors that are associated with intervention responsiveness. Study investigators will use EHR data to identify providers of patients whose hypertension treatment was not intensified. Primary care physicians will then be randomized to one of three arms: pharmacist e-detailing, provider dashboards, or no intervention (control). After the intervention, the investigators will conduct virtual interviews with select providers from each arm. A predictive modeling approach will then be used to identify patient and provider characteristics that are associated with inertia and with responsiveness to each intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 27, 2020
Enrollment StartOct 26, 2021
Primary CompletionAug 8, 2022
Study CompletionFeb 8, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.7 years ago

Interventions

Audit and Feedbackbehavioral

A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.

Pharmacist E-Detailingbehavioral

A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.